Edwards Lifesciences (EW) Still Looks Like a Structural Heart Growth Story, Not Just a TAVR Franchise – Alphastreet

Why Edwards is greater than a single-product medtech story

Edwards Lifesciences (EW) is usually mentioned as if it had been primarily a TAVR firm. That shorthand is comprehensible as a result of transcatheter aortic valve substitute stays its largest enterprise. However the firm’s personal reporting exhibits a broader structural coronary heart platform that features TAVR, transcatheter mitral and tricuspid therapies, and a sturdy surgical franchise.

Within the quarter ended March 31, 2026, Edwards reported whole web gross sales of $1.65 billion. TAVR contributed $1.20 billion, TMTT contributed $175.1 million, and Surgical contributed $276.2 million. That blend nonetheless exhibits TAVR because the financial anchor, nevertheless it additionally exhibits why the funding case shouldn’t cease there. The corporate now has significant progress publicity throughout a number of structural coronary heart classes moderately than one process set alone.

That issues as a result of medtech companies with adjoining progress engines can age higher than single-franchise tales. If TAVR stays wholesome whereas TMTT scales and Surgical continues to carry its place, Edwards can produce a greater-high quality progress profile than traders might assume from a one-product framing.

What the most recent outcomes say about TAVR, TMTT, and surgical momentum

The primary quarter strengthened that broader platform view. In its earnings launch, Edwards stated Q1 gross sales grew 16.7% to $1.65 billion, or 12.7% on a fixed-forex foundation. TAVR gross sales grew 14.4% to $1.20 billion, whereas TMTT gross sales reached $175.1 million. Surgical gross sales elevated 10.1% to $276.2 million.

The section commentary issues as a lot because the headline numbers. Edwards stated TAVR progress mirrored wholesome SAPIEN demand in the US and even sooner progress outdoors the US. For TMTT, the corporate stated greater gross sales of the PASCAL restore system and EVOQUE tricuspid valve substitute system drove progress. In Surgical, Edwards pointed to continued adoption of its RESILIA therapies, together with INSPIRIS, MITRIS, and KONECT.

That’s the actual strategic level. TAVR remains to be the revenue heart, however TMTT is now not simply an R&D choice, and Surgical nonetheless offers related process publicity and product depth.

The corporate’s steerage adjustments additionally help that view. Edwards raised its full-yr 2026 fixed-forex gross sales progress steerage to 9% to 11% from 8% to 10%, and it raised TAVR progress steerage to 7% to 9% from 6% to eight%. It additionally lifted the midpoint of adjusted EPS steerage to a vary of $2.95 to $3.05.

Why stability-sheet energy and capital allocation matter right here

Edwards additionally has monetary flexibility that many medtech names want to have. At March 31, 2026, the corporate reported $2.45 billion of money and money equivalents and $1.23 billion of brief-time period investments, towards lengthy-time period debt of about $598 million. That stability-sheet profile offers administration room to speculate, purchase, and return capital with out relying closely on leverage.

Capital allocation is already displaying up within the numbers. Throughout the quarter, Edwards accomplished a $500 million accelerated share repurchase and stated it nonetheless had about $1.5 billion remaining underneath its share repurchase authorization. That doesn’t create the thesis by itself, nevertheless it does reinforce that Edwards can help progress initiatives whereas nonetheless returning capital.

The quarter additionally included the acquisition of Autus Valve Applied sciences for whole consideration of $128.9 million plus contingent consideration tied to milestones. That’s one other reminder that administration is attempting to widen the structural coronary heart alternative set moderately than merely defend the present TAVR franchise.

What traders ought to watch subsequent

The very first thing to observe is whether or not TMTT can preserve scaling quick sufficient to grow to be extra materials to the group combine. The class remains to be a lot smaller than TAVR, however 51.9% progress within the 10-Q product desk is the type of quantity that may change how the corporate is valued over time if it stays sturdy.

The second is whether or not TAVR stays wholesome with out turning into the entire story once more. Edwards stated common promoting costs had been steady globally and raised full-yr TAVR steerage after the quarter. If TAVR stays stable whereas TMTT expands, the corporate’s progress profile appears extra balanced.

The third is margin and capital self-discipline. Edwards stated it expects full-yr working revenue margin on the excessive finish of its unique 28% to 29% vary. If that holds whereas the corporate funds innovation and buybacks, traders get a cleaner mixture of progress and monetary high quality than a slender system narrative suggests.

Edwards nonetheless relies upon closely on TAVR at present. However the bigger structural coronary heart platform is turning into tougher to disregard, and that’s the a part of the thesis that will matter most over the following few years.

Key Alerts for Traders

• Q1 2026 web gross sales had been $1.65 billion, up 16.7% yr over yr.
• TAVR gross sales had been $1.20 billion, TMTT gross sales had been $175.1 million, and Surgical gross sales had been $276.2 million.
• Edwards raised full-yr 2026 fixed-forex gross sales progress steerage to 9% to 11% and raised TAVR progress steerage to 7% to 9%.
• Money and money equivalents had been about $2.45 billion at March 31, 2026, with lengthy-time period debt of about $598 million.
• The corporate accomplished a $500 million accelerated share repurchase through the quarter.

Sources

1. https://www.sec.gov/Archives/edgar/knowledge/1099800/000109980026000021/ex-991q12026.htm
2. https://www.sec.gov/Archives/edgar/knowledge/1099800/000109980026000026/ew-20260331.htm